Bryan Yoon
Geschäftsführer bei TERNS PHARMACEUTICALS, INC.
Vermögen: 404 371 $ am 30.04.2024
Profil
Bryan Yoon is currently the COO, Secretary & General Counsel at Terns Pharmaceuticals, Inc. He previously worked as the Director at NightstaRx Ltd.
from 2018 to 2019.
From 2013 to 2017, he served as the Secretary & Senior Vice President-Legal Affairs at Intercept Pharmaceuticals, Inc. Bryan also held the position of Secretary & Chief Administrative Officer at LogicBio Therapeutics, Inc. from 2019 to 2020.
Additionally, he worked as the Secretary & General Counsel at Nightstar Therapeutics Ltd.
from 2017 to 2019.
Mr. Yoon completed his undergraduate and graduate degrees at Cornell University in 1999 and 2000 respectively.
He obtained his graduate degree from The University of Michigan Law School in 2005.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 23.01.2024 | 87 149 ( 0,13% ) | 404 371 $ | 30.04.2024 |
Aktive Positionen von Bryan Yoon
| Unternehmen | Position | Beginn |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Geschäftsführer | 01.11.2020 |
Ehemalige bekannte Positionen von Bryan Yoon
| Unternehmen | Position | Ende |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Verwaltungsdirektor | 06.11.2020 |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 07.06.2019 |
| NIGHTSTAR THERAPEUTICS PLC | General Counsel | 01.06.2019 |
| INTERCEPT PHARMACEUTICALS, INC. | General Counsel | 01.11.2017 |
Ausbildung von Bryan Yoon
| Cornell University | Graduate Degree |
| The University of Michigan Law School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
